Company Overview and News

 
Axis Bank Limited - Analysts/Institutional Investor Meet/Con. Call Updates

1h nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
AXBKY AXBA AXB AXISBANK 532215

 
SBI to raise $500 million in maiden green bond sale

3h moneycontrol
The country's largest lender State Bank is in the international bond market to raise nearly $500 million in green bonds, making it the maiden issuance for the lender.
AXBKY YESBANK AXBA AXB AXISBANK 532648 YYBKY 532215 SBAZ

 
Axis Bank Limited - Updates

4h nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
AXBKY AXBA AXB AXISBANK 532215

 
Axis Bank Limited - Analysts/Institutional Investor Meet/Con. Call Updates

8h nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
AXBKY AXBA AXB AXISBANK 532215

4
Sensex recovers by 142 points in opening trade, Nifty above 11,300

9h freepressjournal.in
Mumbai: The BSE Sensex rebounded over 100 points in opening trade Wednesday on value-buying in recently battered stocks amid strength in the rupee and positive global cues. The 30-share BSE index recovered by 142.26 points, or 0.38 per cent, to 37,432.93 in opening trade. The index had lost almost 800 points in the previous two sessions as rupee woes and trade war worries spooked investors. The NSE Nifty was up 50.
BAJAJ-AUTO 532977 BHRQY 533278 532215 500470 532187 AXISBANK 500570 BHARTIARTL TATAMOTORS CLNDY AXB INDUSINDBK IBN AXBKY 532454 AXBA ICICIBANK TTST TATASTEEL TATLY 532174 COALINDIA TTM

4
Stock investors lose Rs 2.72 lakh cr in two days of market fall

2018-09-18 thehindubusinessline
Sensex on Tuesday tumbled by about 295 points to close at 37,290.67. File Photo - BusinessLine
BAJAJ-AUTO AXBKY AXBA AXB AXISBANK 532977 500570 TATAMOTORS 532215 TTM

1
Rupee, trade war woes pull down Sensex by 505 pts

2018-09-18 freepressjournal.in
Mumbai : The BSE benchmark Sensex on Monday crashed over 505 points to slip below the 38,000-level, snapping its two sessions of gains, as rupee woes and global trade war worries spooked investors despite the government announcing measures to stem a steep fall in the domestic currency.
YESBANK AXB IBN 532648 YYBKY 532215 AXBKY AXBA ICICIBANK HDB AXISBANK 532174 500180 HDFCBANK

 
Independent director of Jaypee Infratech ‘Sham Lal Mohan’ resigns

2018-09-17 freepressjournal.in
New Delhi: Jaypee Infratech, which is facing insolvency proceedings, Monday said that the company’s independent director Sham Lal Mohan has resigned citing personal reasons. Last week, three independent directors Lalit Bhasin, Keshav Prasad Rau and Basant Kumar Goswami had resigned from the board.
UBNC AXB JIPKY IBN JPASSOCIAT 532525 532215 MAHABANK 532532 AXBKY 532179 SYNDIBANK AXBA ICICIBANK 533207 532276 JPINFRATEC CRPKY AXISBANK 532174 CORPBANK

 
Axis Bank Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-09-17 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
AXBKY AXBA AXB AXISBANK 532215

 
Axis Bank Limited - Allotment of ESOP/ESPS

2018-09-17 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
AXBKY AXBA AXB AXISBANK 532215

 
Another independent director of Jaypee Infratech resigns; fourth in last one week

2018-09-17 moneycontrol
Jaypee Infratech, which is facing insolvency proceedings, Monday said that the company's independent director Sham Lal Mohan has resigned citing personal reasons. Last week, three independent directors Lalit Bhasin, Keshav Prasad Rau and Basant Kumar Goswami had resigned from the board.
UBNC AXB JIPKY IBN JPASSOCIAT 532525 532215 MAHABANK 532532 AXBKY 532179 SYNDIBANK AXBA ICICIBANK 533207 532276 JPINFRATEC CRPKY AXISBANK 532174 CORPBANK

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...